Transplant News and Research

RSS

Is 'model health system' Geisinger replicable elsewhere?

Geisinger Health System, in central Pennsylvania, has been widely hailed as a model for health reform by leading Democrats including President Obama, the Philadelphia Inquirer reports. But, its success may hinge on "a rare combination of factors" including "a relative lack of competition, its stable patient base, and the fact that its 800 doctors are on salary," as well as an in-house pharmacy and insurance plan that covers one-third of its patients.

19 Oct 2009

Schering-Plough to present data on boceprevir at the AASLD 2009 Annual Meeting

Schering-Plough announced that data on boceprevir, an investigational hepatitis C virus (HCV) protease inhibitor, will be reported in an oral presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting in Boston, Oct. 30-Nov. 3.

19 Oct 2009

Stem cell treatments could repair the kidney defects associated with Alport syndrome

Several cell-based therapy approaches could provide new treatments for patients with Alport syndrome, reports an upcoming paper in the Journal of the American Society of Nephrology (JASN). "Our study opens up many considerations of how new therapies related to the use of stem cells can be devised for our kidney patients with chronic disease," comments Raghu Kalluri, MD, PhD (Harvard Medical School, Boston, MA).

19 Oct 2009

Institute Curie Hospital in France adds another TomoTherapy radiation therapy system

TomoTherapy Incorporated announced today that the Institute Curie Hospital in France has purchased a second TomoTherapy® radiation therapy system, to support the increasing demand for intensity-modulated radiation therapy (IMRT). The Institute Curie Hospital has been treating cancer patients with TomoTherapy technology since March 2007, when it became the first hospital in France to adopt the technology.

19 Oct 2009

Research programme to develop immunological biomarkers for chronic inflammatory diseases

Persistent inflammation and the activation of the immune system is the key pathological mechanism affecting many long-term conditions, such as rheumatoid arthritis, psoriasis, ulcerative colitis, and Crohn's disease and is the predominant mechanism underlying organ transplant rejection.

19 Oct 2009

Coronary angiography does not affect kidney functioning in CKD patients, reveals study

A screening test that measures whether a patient's heart is healthy enough for a kidney transplant is not as dangerous as once thought, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN).

19 Oct 2009

Research study reveals SFSGD in EGD individuals with GRBWR below 0.8%

Small-for-size graft dysfunction (SFSGD) following living-related liver transplantation (LRLT) is characterized by early graft dysfunction (EGD) when the graft-to-recipient body weight ratio (GRBWR) is below 0.8%.

19 Oct 2009

Fate Therapeutics announces human iPSC generation using a combination of small molecules

Fate Therapeutics, Inc. announced today the generation of human induced-pluripotent stem cells (iPSCs) using a combination of small molecules that significantly improves the speed and efficiency of reprogramming.

19 Oct 2009

MDS secures international cooperation to help Canadian teenager with malignant blood disorder

The Myelodysplastic Syndromes (MDS) Foundation says a wide range of international cooperation has been secured to help 18-year-old Wes Laporte of Ontario get treatment for a life-threatening condition in the US.

15 Oct 2009

Soligenix commences enrollment in its Phase 3 Orbec clinical trial for acute GI GVHD

Soligenix, Inc., formerly known as DOR BioPharma, Inc., a late-stage biotechnology company, announced today that it has initiated enrollment in its confirmatory Phase 3 randomized, double-blind, placebo-controlled, multicenter clinical trial evaluating orBec(®) for the treatment of acute gastrointestinal Graft-versus-Host disease (GI GVHD).

15 Oct 2009

Genzyme ranked third on the global list for best employers

Genzyme Corporation announced today that scientists have again named the company a top employer in a survey ranking the reputations of biotechnology and pharmaceutical companies. Genzyme is ranked third on the global list of 575 companies, the second consecutive year it has achieved this position. Genzyme placed among the top 10 of all biotechnology and pharmaceutical companies in the world for the seventh year in a row.

15 Oct 2009

25-year anniversary of the first neonatal cross-species heart transplantation to be celebrated

Monday, October 26, marks the 25-year anniversary of the first neonatal cross-species heart transplant in history. Dr. Leonard Bailey and a team of doctors at Loma Linda University Medical Center transplanted the heart of a baboon into an infant, born with uniformly lethal heart disease and known to the world as "Baby Fae," on October 26, 1984.

15 Oct 2009

SynCardia Systems' new Companion Driver System receives CE Mark approval

On Oct. 15, SynCardia Systems, Inc., manufacturer of the SynCardia temporary CardioWest™ Total Artificial Heart, announced that its new Companion Driver System has received CE Mark approval to power the Total Artificial Heart in Europe.

15 Oct 2009

Cytheris initiates Phase I/IIa dose escalation study of patients suffering from ICL

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the initiation of a Phase I/IIa dose escalation study of patients suffering from idiopathic CD4 lymphocytopenia (ICL).

15 Oct 2009

More than half RCTs do not report vital information about study populations race, says study

A new study recently published online by the American Heart Journal shows that more than half of all randomized clinical trials, or RCTs, for cardiovascular disease are not reporting vital information about the study populations race or ethnicity. NYU School of Medicine researchers found that out of the 156 cardiovascular disease RCTs analyzed, only 35% of trials reported any information on race or ethnicity between 1970 and 2006. From 2000 to 2006, 46% of trials included that information.

15 Oct 2009

Less expensive anti-rejection drug as effective as more expensive drug, says study

A newer, less expensive drug used to suppress the immune system and prevent organ rejection in kidney and pancreas transplant patients works just as well as its much more expensive counterpart, according to a new study by researchers at Wake Forest University Baptist Medical Center.

15 Oct 2009

SCID infants who receive early bone marrow transplants are likely to have fewer complications

Mention the words "bubble boy" and many will recall David Vetter, the kid with big eyes and a thick thatch of dark hair who died 25 years ago after spending almost the entire 12 years of his life in a germ-free, plastic bubble. David was born with severe combined immune deficiency, or SCID, a condition that robbed him of an immune system.

14 Oct 2009

New UCL cancer research centre launched in UK

A new centre is launched in London today (Wednesday), joining a select group of Cancer Research UK Centres across the UK.

14 Oct 2009

Celling Technologies announces positive outcome of Res-Q System in its initial applications

ThermoGenesis Corp., a leading supplier of innovative products for processing and storing adult stem cells, said today its Res-Q(TM) 60 BMC ("Res-Q") System has demonstrated positive outcomes in its initial applications, according to its orthopedic distribution partner Celling Technologies, a subsidiary of SpineSmith, LLC.

14 Oct 2009

SANUWAVE presents findings on extracorporeal shock wave stimulation of osteoprogenitor cells

SANUWAVE, Inc., an emerging medical technology company focused on the development and commercialization of non-invasive, biological response activating devices in the regenerative medicine area, reported that scientific findings titled “Extracorporeal Shock Wave Stimulation of Osteoprogenitor Cells” were presented at the 2009 International Bone-Tissue-Engineering Congress (“Bone-Tec”) in Hannover, Germany, which was held October 9-11, 2009.

13 Oct 2009

Transplant News and Research

Is 'model health system' Geisinger replicable elsewhere?

Schering-Plough to present data on boceprevir at the AASLD 2009 Annual Meeting

Stem cell treatments could repair the kidney defects associated with Alport syndrome

Institute Curie Hospital in France adds another TomoTherapy radiation therapy system

Research programme to develop immunological biomarkers for chronic inflammatory diseases

Coronary angiography does not affect kidney functioning in CKD patients, reveals study

Research study reveals SFSGD in EGD individuals with GRBWR below 0.8%

Fate Therapeutics announces human iPSC generation using a combination of small molecules

MDS secures international cooperation to help Canadian teenager with malignant blood disorder

Soligenix commences enrollment in its Phase 3 Orbec clinical trial for acute GI GVHD

Genzyme ranked third on the global list for best employers

25-year anniversary of the first neonatal cross-species heart transplantation to be celebrated

SynCardia Systems' new Companion Driver System receives CE Mark approval

Cytheris initiates Phase I/IIa dose escalation study of patients suffering from ICL

More than half RCTs do not report vital information about study populations race, says study

Less expensive anti-rejection drug as effective as more expensive drug, says study

SCID infants who receive early bone marrow transplants are likely to have fewer complications

New UCL cancer research centre launched in UK

Celling Technologies announces positive outcome of Res-Q System in its initial applications

SANUWAVE presents findings on extracorporeal shock wave stimulation of osteoprogenitor cells

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News